Investigational drug · Phase 2
HS-10390
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Kidney Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "HS-10390"
First trial start
2026
May 21, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-10390", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Kidney Disease
Approved drugs for the same conditions: Chronic kidney disease · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-10390" as an intervention, largest first.
- A Study of the Effect and Safety of HS-10390 in the Treatment of Participants With Chronic Kidney DiseasePivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07555054 · 182 participants (planned) · Start May 21, 2026 · Primary completion Nov 11, 2027
Drug: HS-10390; HS-10390 and 2 more · For: Chronic Kidney Disease
Sites: Guangzhou, China
- A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA NephropathyStatus unknown
Hansoh BioMedical R&D CompanyIndustry
NCT06635772 · 90 participants (planned) · Start Nov 2024 · Primary completion Dec 1, 2025
Drug: HS-10390; Irbesartan · For: Immunoglobulin a Nephropathy
Sites: Beijing, China
- A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy SubjectsStatus unknown
Hansoh BioMedical R&D CompanyIndustry
NCT05942625 · 84 participants (planned) · Start May 23, 2023 · Primary completion Jun 30, 2024
Drug: HS-10390 tablet; Placebo tablet · For: IgA Nephropathy; Focal Segmental Glomerulosclerosis
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Kidney Disease
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- HRS-1780Phase 33 trials
Shandong Suncadia Medicine Co., Ltd. · Chronic Kidney Disease, Uncontrolled or Resistant Hypertension, Primary Aldosteronism
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.